Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype
2016
Аутори
Virijević, MarijanaKaran-Đurašević, Teodora
Marjanović, Irena
Tošić, Nataša
Mitrović, Mirjana
Djunić, Irena
Čolović, Nataša
Vidović, Ana
Suvajdžić-Vuković, Nada
Tomin, Dragica
Pavlović, Sonja
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Background. Mutations in the isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes are frequent molecular lesions in acute myeloid leukaemia with normal karyotype (AML-NK). The effects of IDH mutations on clinical features and treatment outcome in AML-NK have been widely investigated, but only a few studies monitored these mutations during follow-up. Patients and methods. In our study samples from 110 adult de novo AML-NK were studied for the presence of IDH1 and IDH2 mutations, their associations with other prognostic markers and disease outcome. We also analyzed the stability of these mutations during the course of the disease in complete remission (CR) and relapse. Results. IDH mutations were found in 25 (23%) patients. IDH+ patients tend to have lower CR rate compared to IDH-patients (44% vs 62.2%, p = 0.152), and had slightly lower disease free survival (12 months vs 17 months; p = 0.091). On the other hand, the presence of IDH mutations had significant impact on overall survival... (2 vs 7 months; p = 0.039). The stability of IDH mutations were studied sequentially in 19 IDH+ patients. All of them lost the mutation in CR, and the same IDH mutations were detected in relapsed samples. Conclusions. Our study shows that the presence of IDH mutations confer an adverse effect in AML-NK patients, which in combination with other molecular markers can lead to an improved risk stratification and better treatment. Also, IDH mutations are very stable during the course of the disease and can be potentially used as markers for minimal residual disease detection.
Кључне речи:
normal karyotype / IDH2 mutations / IDH1 mutations / acute myeloid leukaemiaИзвор:
Radiology and Oncology, 2016, 50, 4, 385-393Издавач:
- Walter De Gruyter Gmbh, Berlin
Финансирање / пројекти:
- Ретке болести: молекуларна патофизиологија, дијагностички и терапијски модалитети и социјални, етички и правни аспекти (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41004)
DOI: 10.1515/raon-2016-0044
ISSN: 1318-2099
WoS: 000388229400006
Scopus: 2-s2.0-84997523755
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Virijević, Marijana AU - Karan-Đurašević, Teodora AU - Marjanović, Irena AU - Tošić, Nataša AU - Mitrović, Mirjana AU - Djunić, Irena AU - Čolović, Nataša AU - Vidović, Ana AU - Suvajdžić-Vuković, Nada AU - Tomin, Dragica AU - Pavlović, Sonja PY - 2016 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/963 AB - Background. Mutations in the isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes are frequent molecular lesions in acute myeloid leukaemia with normal karyotype (AML-NK). The effects of IDH mutations on clinical features and treatment outcome in AML-NK have been widely investigated, but only a few studies monitored these mutations during follow-up. Patients and methods. In our study samples from 110 adult de novo AML-NK were studied for the presence of IDH1 and IDH2 mutations, their associations with other prognostic markers and disease outcome. We also analyzed the stability of these mutations during the course of the disease in complete remission (CR) and relapse. Results. IDH mutations were found in 25 (23%) patients. IDH+ patients tend to have lower CR rate compared to IDH-patients (44% vs 62.2%, p = 0.152), and had slightly lower disease free survival (12 months vs 17 months; p = 0.091). On the other hand, the presence of IDH mutations had significant impact on overall survival (2 vs 7 months; p = 0.039). The stability of IDH mutations were studied sequentially in 19 IDH+ patients. All of them lost the mutation in CR, and the same IDH mutations were detected in relapsed samples. Conclusions. Our study shows that the presence of IDH mutations confer an adverse effect in AML-NK patients, which in combination with other molecular markers can lead to an improved risk stratification and better treatment. Also, IDH mutations are very stable during the course of the disease and can be potentially used as markers for minimal residual disease detection. PB - Walter De Gruyter Gmbh, Berlin T2 - Radiology and Oncology T1 - Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype EP - 393 IS - 4 SP - 385 VL - 50 DO - 10.1515/raon-2016-0044 ER -
@article{ author = "Virijević, Marijana and Karan-Đurašević, Teodora and Marjanović, Irena and Tošić, Nataša and Mitrović, Mirjana and Djunić, Irena and Čolović, Nataša and Vidović, Ana and Suvajdžić-Vuković, Nada and Tomin, Dragica and Pavlović, Sonja", year = "2016", abstract = "Background. Mutations in the isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes are frequent molecular lesions in acute myeloid leukaemia with normal karyotype (AML-NK). The effects of IDH mutations on clinical features and treatment outcome in AML-NK have been widely investigated, but only a few studies monitored these mutations during follow-up. Patients and methods. In our study samples from 110 adult de novo AML-NK were studied for the presence of IDH1 and IDH2 mutations, their associations with other prognostic markers and disease outcome. We also analyzed the stability of these mutations during the course of the disease in complete remission (CR) and relapse. Results. IDH mutations were found in 25 (23%) patients. IDH+ patients tend to have lower CR rate compared to IDH-patients (44% vs 62.2%, p = 0.152), and had slightly lower disease free survival (12 months vs 17 months; p = 0.091). On the other hand, the presence of IDH mutations had significant impact on overall survival (2 vs 7 months; p = 0.039). The stability of IDH mutations were studied sequentially in 19 IDH+ patients. All of them lost the mutation in CR, and the same IDH mutations were detected in relapsed samples. Conclusions. Our study shows that the presence of IDH mutations confer an adverse effect in AML-NK patients, which in combination with other molecular markers can lead to an improved risk stratification and better treatment. Also, IDH mutations are very stable during the course of the disease and can be potentially used as markers for minimal residual disease detection.", publisher = "Walter De Gruyter Gmbh, Berlin", journal = "Radiology and Oncology", title = "Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype", pages = "393-385", number = "4", volume = "50", doi = "10.1515/raon-2016-0044" }
Virijević, M., Karan-Đurašević, T., Marjanović, I., Tošić, N., Mitrović, M., Djunić, I., Čolović, N., Vidović, A., Suvajdžić-Vuković, N., Tomin, D.,& Pavlović, S.. (2016). Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype. in Radiology and Oncology Walter De Gruyter Gmbh, Berlin., 50(4), 385-393. https://doi.org/10.1515/raon-2016-0044
Virijević M, Karan-Đurašević T, Marjanović I, Tošić N, Mitrović M, Djunić I, Čolović N, Vidović A, Suvajdžić-Vuković N, Tomin D, Pavlović S. Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype. in Radiology and Oncology. 2016;50(4):385-393. doi:10.1515/raon-2016-0044 .
Virijević, Marijana, Karan-Đurašević, Teodora, Marjanović, Irena, Tošić, Nataša, Mitrović, Mirjana, Djunić, Irena, Čolović, Nataša, Vidović, Ana, Suvajdžić-Vuković, Nada, Tomin, Dragica, Pavlović, Sonja, "Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype" in Radiology and Oncology, 50, no. 4 (2016):385-393, https://doi.org/10.1515/raon-2016-0044 . .